CHU Besançon-Medical oncology ( Site 1101)

Besançon, Doubs 25000

0 studies enrolling now · 1 studies all time

What they study most

Neoplasm Malignant

Studies at this site

• Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) — Running, not enrolling